Abstract
Uncaging chemistry catalyzed by transition metals is developed from deprotection reactions and metal-organic catalytic reactions. Also, it has the characteristics of high efficiency, simplicity and rapidity in the living biological system. In the past decade, metal encapsulation systems (such as nanoparticles) and metal complexes have been developed to reveal the reactivity of transition metals (including palladium, ruthenium, and gold) in biological systems. Metal nanostructures provide huge possibilities for targeted drug delivery, detection, diagnosis and imaging. So far, palladium, ruthenium and gold nano-architectures have dominated the field, but there are some problems that hinder their wide application in clinical practice. In this review, based on palladium, ruthenium, gold and their complexes, the application of prodrug design through uncaging reaction has been widely discussed.
Keywords: Transition metals, Prodrug design, Biocompatibility, Uncaging chemistry, Targeted drug delivery, TM catalyst.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Transition Metal-mediated Uncaging Chemistry in Prodrug Design
Volume: 21 Issue: 24
Author(s): Hai Yang Shu, Ren De Zhu, Jing Wu, Xin Hua Liu and Jing Bo Shi*
Affiliation:
- School of Pharmacy, Anhui Medical University, Hefei, 230032,China
Keywords: Transition metals, Prodrug design, Biocompatibility, Uncaging chemistry, Targeted drug delivery, TM catalyst.
Abstract: Uncaging chemistry catalyzed by transition metals is developed from deprotection reactions and metal-organic catalytic reactions. Also, it has the characteristics of high efficiency, simplicity and rapidity in the living biological system. In the past decade, metal encapsulation systems (such as nanoparticles) and metal complexes have been developed to reveal the reactivity of transition metals (including palladium, ruthenium, and gold) in biological systems. Metal nanostructures provide huge possibilities for targeted drug delivery, detection, diagnosis and imaging. So far, palladium, ruthenium and gold nano-architectures have dominated the field, but there are some problems that hinder their wide application in clinical practice. In this review, based on palladium, ruthenium, gold and their complexes, the application of prodrug design through uncaging reaction has been widely discussed.
Export Options
About this article
Cite this article as:
Shu Yang Hai , De Zhu Ren , Wu Jing , Liu Hua Xin and Shi Bo Jing *, Transition Metal-mediated Uncaging Chemistry in Prodrug Design, Current Topics in Medicinal Chemistry 2021; 21 (24) . https://dx.doi.org/10.2174/1568026621666210624113313
DOI https://dx.doi.org/10.2174/1568026621666210624113313 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic
and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Current Radiopharmaceuticals The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry C-glycosyl Flavone from Urginea indica Inhibits Growth and Dissemination of Ehrlich Ascites Carcinoma Cells in Mice
Anti-Cancer Agents in Medicinal Chemistry Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Factors Affecting the Metabolite Productions in Endophytes: Biotechnological Approaches for Production of Metabolites
Current Medicinal Chemistry The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry